Jump to section

References

Trials

Economics

Properties

Spectra

Taxonomy

Doxylamine

Targets (3)Enzymes (1)Biointeractions (3)

Identification

Name

Doxylamine

Accession Number

DB00366 (APRD00937)

Type

Small Molecule

Groups

Approved, Vet approved

Description

Histamine H1 antagonist with pronounced sedative properties. It is used in allergies and as an antitussive, antiemetic, and hypnotic. Doxylamine has also been administered in veterinary applications and was formerly used in parkinsonism. [PubChem]

Structure

Similar Structures

Synonyms

2-(alpha-(2-(Dimethylamino)ethoxy)-alpha-methylbenzyl)pyridine
2-Dimethylaminoethoxyphenylmethyl-2-picoline
Dossilamina
Doxilamina
Doxilminio
Doxylaminum
N,N-Dimethyl-2-(1-phenyl-1-(2-pyridinyl)ethoxy)ethanamine
Phenyl-2-pyridylmethyl-beta-N,N-dimethylaminoethyl ether

Product Ingredients

Ingredient	UNII	CAS	InChI Key
Doxylamine succinate	V9BI9B5YI2	562-10-7	KBAUFVUYFNWQFM-UHFFFAOYSA-N

Product Images

Over the Counter Products

Name	Dosage	Strength	Route	Labeller	Marketing Start	Marketing End
7 Select Sleep Aid	Tablet	25 mg/1	Oral	7 Eleven	2014-08-05	Not applicable
Basic Care Sleep Aid	Tablet	25 mg/1	Oral	L. Perrigo Company	2018-03-06	Not applicable
Care One Sleep Aid	Tablet	25 mg/1	Oral	American Sales Company	2004-06-29	Not applicable
CareOne Nighttime Sleep Aid	Tablet	25 mg/1	Oral	American Sales Company	2016-05-06	Not applicable
Equaline Sleep Aid	Tablet	25 mg/1	Oral	Supervalu	2004-08-10	2017-12-22
Good Neighbor Pharmacy Sleep Aid	Tablet	25 mg/1	Oral	Amerisource Bergen	1997-06-26	Not applicable
Good sense sleep aid	Tablet	25 mg/1	Oral	L. Perrigo Company	1997-04-14	Not applicable
Harris Teeter Sleep Aid	Tablet	25 mg/1	Oral	Harris Teeter	2015-11-21	Not applicable
Health Mart Sleep Aid	Tablet	25 mg/1	Oral	Mc Kesson	2011-11-21	Not applicable
Healthy Accents Sleep Aid	Tablet	25 mg/1	Oral	Dza Brands,	2011-06-06	Not applicable

Mixture Products

Name	Ingredients	Dosage	Route	Labeller	Marketing Start	Marketing End
7 Select Night Time Relief	Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1)	Capsule, gelatin coated	Oral	7 Eleven	2014-04-17	Not applicable
7 Select Night Time Relief	Doxylamine succinate (12.5 mg/30mL) + Acetaminophen (650 mg/30mL) + Dextromethorphan hydrobromide (30 mg/30mL)	Solution	Oral	7 Eleven	2014-08-05	Not applicable
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HCl	Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)	Capsule, liquid filled	Oral	Cvs Pharmacy,inc	2017-07-07	Not applicable
Acetaminophen Dextromethorphan HBr Doxylamine succinate Phenylephrine HCl	Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)	Capsule, liquid filled	Oral	CVS Health	2017-11-30	Not applicable
ACETAMINOPHEN DEXTROMETHORPHAN HYDROBROMIDE and DOXYLAMINE SUCCINATE	Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1)	Capsule, liquid filled	Oral	J.P. BUSINESS ENTERPRISE	2014-12-01	Not applicable
Acetaminophen Dextromethorphan Hydrobromide Doxylamine Succinate Phenylephrine Hydrochloride	Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine hydrochloride (5 mg/1)	Capsule, liquid filled	Oral	Granules India Limited	2017-07-07	Not applicable
ACETAMINOPHEN, DEXTROMETHORPHAN HYDROBROMIDE, and DOXYLAMINE SUCCINATE	Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (15 mg/1)	Capsule, liquid filled	Oral	Spirit Pharmaceuticals, Llc	2009-10-15	Not applicable
Acetaminophen,Dextromethorphan,Doxylamine	Doxylamine succinate (6.25 mg/1) + Acetaminophen (325 mg/1) + Dextromethorphan hydrobromide (10 mg/1)	Capsule, liquid filled	Oral	Agile Pharmachem	2014-05-01	Not applicable
Acetaminophen/pseudoephedrine/dextromethorphan/doxylamine	Doxylamine succinate (6.25 mg) + Acetaminophen (325 mg) + Dextromethorphan hydrobromide (15 mg) + Pseudoephedrine hydrochloride (30 mg)	Capsule	Oral	Apotex Corporation	Not applicable	Not applicable
Alka-Seltzer Plus Day and Night Cold	Doxylamine succinate (6.25 mg/1) + Acetylsalicylic acid (325 mg/1) + Acetylsalicylic acid (500 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Dextromethorphan hydrobromide (10 mg/1) + Phenylephrine bitartrate (7.8 mg/1) + Phenylephrine bitartrate (7.8 mg/1)	Kit		Bayer Health Care Llc.	2015-01-09	2018-11-01

Categories

UNII

95QB77JKPL

CAS number

469-21-6

Weight

Average: 270.3694
Monoisotopic: 270.173213336

Chemical Formula

C₁₇H₂₂N₂O

InChI Key

HCFDWZZGGLSKEP-UHFFFAOYSA-N

InChI

InChI=1S/C17H22N2O/c1-17(20-14-13-19(2)3,15-9-5-4-6-10-15)16-11-7-8-12-18-16/h4-12H,13-14H2,1-3H3

IUPAC Name

dimethyl({2-[1-phenyl-1-(pyridin-2-yl)ethoxy]ethyl})amine

SMILES

CN(C)CCOC(C)(C1=CC=CC=C1)C1=CC=CC=N1

Pharmacology

Indication

Used alone as a short-term sleep aid, in combination with other drugs as a night-time cold and allergy relief drug. Also used in combination with Vitamin B6 (pyridoxine) to prevent morning sickness in pregnant women.

Structured Indications

Pharmacodynamics

Doxylamine is an antihistamine commonly used as a sleep aid. This drug is also used to relieve symptoms of hay fever (allergic rhinitis), hives (rash or itching), and other allergic reactions. Doxylamine is a member of the ethanolamine class of antihistamines and has anti-allergy power far superior to virtually every other antihistamine on the market, with the exception of diphenhydramine (Benadryl). It is also the most powerful over-the-counter sedative available in the United States, and more sedating than many prescription hypnotics. In a study, it was found to be superior to even the barbiturate, phenobarbital for use as a sedative. Doxylamine is also a potent anticholinergic.

Mechanism of action

Like other antihistamines, doxylamine acts by competitively inhibiting histamine at H1 receptors. It also has substantial sedative and anticholinergic effects.

Target	Actions	Organism
AHistamine H1 receptor	antagonist	Human
UMuscarinic acetylcholine receptor M1	antagonist	Human
UNuclear receptor subfamily 1 group I member 3	Not Available	Human

Absorption

Readily absorbed via the gastrointestinal tract.

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism

Hepatic.

Route of elimination

Not Available

Half life

10 hours

Clearance

Not Available

Toxicity

Signs of overdose include wheezing, tightness in the chest, fever, itching, bad cough, blue skin color, fits, swelling of face, lips, tongue, or throat.

Affected organisms

Humans and other mammals

Pathways

Pathway	Category
Doxylamine H1-Antihistamine Action	Drug action

Pharmacogenomic Effects/ADRs

Not Available

Interactions

Drug Interactions

Drug	Interaction	Drug group
2,5-Dimethoxy-4-ethylamphetamine	2,5-Dimethoxy-4-ethylamphetamine may decrease the sedative activities of Doxylamine.	Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamine	2,5-Dimethoxy-4-ethylthioamphetamine may decrease the sedative activities of Doxylamine.	Experimental
3,4-Methylenedioxyamphetamine	3,4-Methylenedioxyamphetamine may decrease the sedative activities of Doxylamine.	Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamine	4-Bromo-2,5-dimethoxyamphetamine may decrease the sedative activities of Doxylamine.	Experimental, Illicit
7-Nitroindazole	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of 7-Nitroindazole.	Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline	7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline may increase the anticholinergic activities of Doxylamine.	Experimental
Acepromazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Acepromazine.	Approved, Vet Approved
Aceprometazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aceprometazine.	Approved
Adipiplon	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Adipiplon.	Investigational
Agomelatine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Agomelatine.	Approved, Investigational
Alaproclate	The risk or severity of adverse effects can be increased when Doxylamine is combined with Alaproclate.	Experimental
Alfaxalone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfaxalone.	Vet Approved
Alfentanil	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alfentanil.	Approved, Illicit
Allopregnanolone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Allopregnanolone.	Investigational
Alphacetylmethadol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alphacetylmethadol.	Experimental, Illicit
Alphaprodine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alphaprodine.	Illicit
Alprazolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Alprazolam.	Approved, Illicit, Investigational
Amisulpride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amisulpride.	Approved, Investigational
Amitriptyline	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amitriptyline.	Approved
Amobarbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amobarbital.	Approved, Illicit
Amoxapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amoxapine.	Approved
Amperozide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Amperozide.	Experimental
Amphetamine	Amphetamine may increase the anticholinergic activities of Doxylamine.	Approved, Illicit, Investigational
Aripiprazole	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Aripiprazole.	Approved, Investigational
Articaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Articaine.	Approved
Asenapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Asenapine.	Approved
Azaperone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Azaperone.	Investigational, Vet Approved
Azelastine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.	Approved
Baclofen	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Baclofen.	Approved
Barbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Barbital.	Illicit
Benmoxin	Benmoxin may increase the anticholinergic activities of Doxylamine.	Withdrawn
Benperidol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benperidol.	Approved, Investigational
Benzocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzocaine.	Approved, Investigational
Benzphetamine	Benzphetamine may decrease the sedative activities of Doxylamine.	Approved, Illicit
Benzyl alcohol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Benzyl alcohol.	Approved
Benzylpenicilloyl Polylysine	Doxylamine may decrease effectiveness of Benzylpenicilloyl Polylysine as a diagnostic agent.	Approved
Betahistine	The therapeutic efficacy of Betahistine can be decreased when used in combination with Doxylamine.	Approved, Investigational
Brexpiprazole	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brexpiprazole.	Approved, Investigational
Brimonidine	Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved
Brofaromine	Brofaromine may increase the anticholinergic activities of Doxylamine.	Experimental
Bromazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromazepam.	Approved, Illicit, Investigational
Bromisoval	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromisoval.	Experimental
Bromperidol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bromperidol.	Approved, Investigational
Brompheniramine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brompheniramine.	Approved
Brotizolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Brotizolam.	Approved, Investigational, Withdrawn
Bupivacaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Bupivacaine.	Approved, Investigational
Buprenorphine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.	Approved, Illicit, Investigational, Vet Approved
Buspirone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Buspirone.	Approved, Investigational
Butabarbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butabarbital.	Approved, Illicit
Butacaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butacaine.	Vet Approved
Butalbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butalbital.	Approved, Illicit
Butamben	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butamben.	Approved, Withdrawn
Butethal	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butethal.	Approved, Illicit
Butorphanol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Butorphanol.	Approved, Illicit, Vet Approved
Canertinib	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Canertinib.	Investigational
Carbamazepine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbamazepine.	Approved, Investigational
Carbinoxamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carbinoxamine.	Approved
Carfentanil	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carfentanil.	Illicit, Investigational, Vet Approved
Carisoprodol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Carisoprodol.	Approved
Caroxazone	Caroxazone may increase the anticholinergic activities of Doxylamine.	Withdrawn
Cetirizine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cetirizine.	Approved
Chloral hydrate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloral hydrate.	Approved, Illicit, Investigational, Vet Approved
Chlordiazepoxide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlordiazepoxide.	Approved, Illicit, Investigational
Chlormezanone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlormezanone.	Approved, Investigational, Withdrawn
Chloroprocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chloroprocaine.	Approved
Chlorphenamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorphenamine.	Approved
Chlorphentermine	Chlorphentermine may decrease the sedative activities of Doxylamine.	Illicit, Withdrawn
Chlorpromazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorpromazine.	Approved, Investigational, Vet Approved
Chlorprothixene	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.	Approved, Investigational, Withdrawn
Chlorzoxazone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Chlorzoxazone.	Approved
Cinchocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cinchocaine.	Approved, Vet Approved
Citalopram	The risk or severity of adverse effects can be increased when Doxylamine is combined with Citalopram.	Approved
Clemastine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clemastine.	Approved, Investigational
Clidinium	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.	Approved
Clobazam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clobazam.	Approved, Illicit
clomethiazole	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of clomethiazole.	Investigational
Clomipramine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clomipramine.	Approved, Investigational, Vet Approved
Clonazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonazepam.	Approved, Illicit
Clonidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clonidine.	Approved
Clopenthixol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clopenthixol.	Experimental
Clorazepate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clorazepate.	Approved, Illicit
Clothiapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clothiapine.	Experimental
Clozapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Clozapine.	Approved
Cocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cocaine.	Approved, Illicit
Codeine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Codeine.	Approved, Illicit
Cyclizine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclizine.	Approved
Cyclobenzaprine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclobenzaprine.	Approved
Cyclopropane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyclopropane.	Experimental
Cyproheptadine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.	Approved
Dantrolene	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dantrolene.	Approved, Investigational
Dapiprazole	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dapiprazole.	Approved
Dapoxetine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Dapoxetine.	Investigational
Deramciclane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Deramciclane.	Investigational
Desflurane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desflurane.	Approved
Desipramine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desipramine.	Approved, Investigational
Desloratadine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Desloratadine.	Approved, Investigational
Desvenlafaxine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Desvenlafaxine.	Approved, Investigational
Detomidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Detomidine.	Vet Approved
Dexbrompheniramine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexbrompheniramine.	Approved
Dexmedetomidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dexmedetomidine.	Approved, Vet Approved
Dextroamphetamine	Dextroamphetamine may decrease the sedative activities of Doxylamine.	Approved, Illicit
Dextromoramide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextromoramide.	Experimental, Illicit
Dextropropoxyphene	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dextropropoxyphene.	Approved, Illicit, Investigational, Withdrawn
Dezocine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dezocine.	Approved, Investigational
Diazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diazepam.	Approved, Illicit, Investigational, Vet Approved
Diethyl ether	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diethyl ether.	Experimental
Diethylpropion	Diethylpropion may decrease the sedative activities of Doxylamine.	Approved, Illicit
Difenoxin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Difenoxin.	Approved, Illicit
Dihydrocodeine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydrocodeine.	Approved, Illicit
Dihydroetorphine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydroetorphine.	Experimental, Illicit
Dihydromorphine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dihydromorphine.	Experimental, Illicit
Dimenhydrinate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dimenhydrinate.	Approved
Diphenhydramine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.	Approved, Investigational
Diphenoxylate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Diphenoxylate.	Approved, Illicit
Dixyrazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dixyrazine.	Experimental
Doramectin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doramectin.	Vet Approved
Doxepin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Doxepin.	Approved, Investigational
DPDPE	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of DPDPE.	Experimental
Dronabinol	Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved, Illicit
Droperidol	Droperidol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved, Vet Approved
Drotebanol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.	Experimental, Illicit
Duloxetine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Duloxetine.	Approved
Dyclonine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Dyclonine.	Approved
Ecgonine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecgonine.	Experimental, Illicit
Ecopipam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ecopipam.	Investigational
Efavirenz	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Efavirenz.	Approved, Investigational
Eltanolone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eltanolone.	Investigational
Enflurane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Enflurane.	Approved, Investigational, Vet Approved
Entacapone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Entacapone.	Approved, Investigational
Escitalopram	The risk or severity of adverse effects can be increased when Doxylamine is combined with Escitalopram.	Approved, Investigational
Estazolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Estazolam.	Approved, Illicit
Eszopiclone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Eszopiclone.	Approved, Investigational
Ethanol	Ethanol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved
Ethchlorvynol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethchlorvynol.	Approved, Illicit, Withdrawn
Ethosuximide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethosuximide.	Approved
Ethotoin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethotoin.	Approved
Ethyl carbamate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl carbamate.	Withdrawn
Ethyl chloride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl chloride.	Approved, Experimental, Investigational
Ethyl loflazepate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethyl loflazepate.	Approved, Illicit
Ethylmorphine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ethylmorphine.	Approved, Illicit
Etidocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etidocaine.	Approved
Etifoxine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etifoxine.	Investigational, Withdrawn
Etizolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etizolam.	Approved
Etomidate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etomidate.	Approved
Etoperidone	The risk or severity of adverse effects can be increased when Doxylamine is combined with Etoperidone.	Withdrawn
Etorphine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Etorphine.	Illicit, Vet Approved
Ezogabine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ezogabine.	Approved, Investigational
Felbamate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Felbamate.	Approved
Fencamfamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fencamfamine.	Approved, Illicit, Withdrawn
Fentanyl	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fentanyl.	Approved, Illicit, Investigational, Vet Approved
Fexofenadine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fexofenadine.	Approved, Investigational
Flibanserin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flibanserin.	Approved, Investigational
Fluanisone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluanisone.	Experimental
Fludiazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fludiazepam.	Approved, Illicit
Flunarizine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunarizine.	Approved
Flunitrazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flunitrazepam.	Approved, Illicit
Fluoxetine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Fluoxetine.	Approved, Vet Approved
Flupentixol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flupentixol.	Approved, Investigational, Withdrawn
Fluphenazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluphenazine.	Approved
Flurazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Flurazepam.	Approved, Illicit, Investigational
Fluspirilene	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluspirilene.	Approved, Investigational
Fluticasone propionate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluticasone propionate.	Approved
Fluvoxamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fluvoxamine.	Approved, Investigational
Fosphenytoin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fosphenytoin.	Approved, Investigational
Fospropofol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Fospropofol.	Approved, Illicit, Investigational
Furazolidone	Furazolidone may increase the anticholinergic activities of Doxylamine.	Approved, Investigational, Vet Approved
Gabapentin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin.	Approved, Investigational
Gabapentin Enacarbil	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gabapentin Enacarbil.	Approved, Investigational
Gamma Hydroxybutyric Acid	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gamma Hydroxybutyric Acid.	Approved, Illicit, Investigational
Gepefrine	Gepefrine may decrease the sedative activities of Doxylamine.	Experimental
Gepirone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Gepirone.	Investigational
Glutethimide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Glutethimide.	Approved, Illicit
Guanfacine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Guanfacine.	Approved, Investigational
Halazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Halazepam.	Approved, Illicit, Withdrawn
Haloperidol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Haloperidol.	Approved
Halothane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Halothane.	Approved, Vet Approved
Harmaline	Harmaline may increase the anticholinergic activities of Doxylamine.	Experimental
Heroin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Heroin.	Approved, Illicit, Investigational
Hexobarbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hexobarbital.	Approved
Hyaluronidase	The therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Doxylamine.	Approved, Investigational
Hydracarbazine	Hydracarbazine may increase the anticholinergic activities of Doxylamine.	Experimental
Hydrocodone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.	Approved, Illicit
Hydromorphone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Hydromorphone.	Approved, Illicit
Hydroxyamphetamine	Hydroxyamphetamine may decrease the sedative activities of Doxylamine.	Approved
Hydroxyzine	Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved
Iloperidone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Iloperidone.	Approved
Imipramine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Imipramine.	Approved
Indalpine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Indalpine.	Investigational, Withdrawn
Indiplon	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Indiplon.	Investigational
Iofetamine I-123	Iofetamine I-123 may decrease the sedative activities of Doxylamine.	Approved
Iproclozide	Iproclozide may increase the anticholinergic activities of Doxylamine.	Withdrawn
Iproniazid	Iproniazid may increase the anticholinergic activities of Doxylamine.	Withdrawn
Isocarboxazid	Isocarboxazid may increase the anticholinergic activities of Doxylamine.	Approved
Isoflurane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Isoflurane.	Approved, Vet Approved
Ketamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketamine.	Approved, Vet Approved
Ketazolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketazolam.	Approved
Ketobemidone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ketobemidone.	Approved, Investigational
Lamotrigine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.	Approved, Investigational
Levetiracetam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levetiracetam.	Approved, Investigational
Levobupivacaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levobupivacaine.	Approved, Investigational
Levocabastine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocabastine.	Approved, Investigational
Levocetirizine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levocetirizine.	Approved
Levodopa	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levodopa.	Approved
Levomethadyl Acetate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levomethadyl Acetate.	Approved, Investigational
Levomilnacipran	The risk or severity of adverse effects can be increased when Doxylamine is combined with Levomilnacipran.	Approved, Investigational
Levorphanol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Levorphanol.	Approved
Lidocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lidocaine.	Approved, Vet Approved
Lisdexamfetamine	Lisdexamfetamine may decrease the sedative activities of Doxylamine.	Approved, Investigational
Lithium	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lithium.	Approved
Lofentanil	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lofentanil.	Illicit
Lofexidine	The therapeutic efficacy of Doxylamine can be increased when used in combination with Lofexidine.	Approved, Investigational
Loprazolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loprazolam.	Experimental
Loratadine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loratadine.	Approved, Investigational
Lorazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lorazepam.	Approved
Lormetazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lormetazepam.	Approved
Loxapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Loxapine.	Approved
Lurasidone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Lurasidone.	Approved, Investigational
Magnesium sulfate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Magnesium sulfate.	Approved, Investigational, Vet Approved
Maprotiline	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.	Approved, Investigational
Mebanazine	Mebanazine may increase the anticholinergic activities of Doxylamine.	Withdrawn
Mebicar	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mebicar.	Experimental
Meclizine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meclizine.	Approved
Medazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Medazepam.	Experimental
Medetomidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Medetomidine.	Vet Approved
Melatonin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Melatonin.	Approved, Nutraceutical, Vet Approved
Melperone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Melperone.	Approved, Investigational
Mephedrone	Mephedrone may decrease the sedative activities of Doxylamine.	Investigational
Mephentermine	Mephentermine may decrease the sedative activities of Doxylamine.	Approved
Mepivacaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mepivacaine.	Approved, Vet Approved
Meprobamate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meprobamate.	Approved, Illicit
Meptazinol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Meptazinol.	Experimental
Mesoridazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mesoridazine.	Approved, Investigational
Metaxalone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Metaxalone.	Approved
Methadone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadone.	Approved
Methadyl Acetate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methadyl Acetate.	Approved, Illicit
Methamphetamine	Methamphetamine may decrease the sedative activities of Doxylamine.	Approved, Illicit
Methapyrilene	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methapyrilene.	Withdrawn
Methaqualone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methaqualone.	Illicit, Withdrawn
Methocarbamol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methocarbamol.	Approved, Vet Approved
Methohexital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methohexital.	Approved
Methotrimeprazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.	Approved, Investigational
Methoxyflurane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methoxyflurane.	Approved, Investigational, Vet Approved
Methoxyphenamine	Methoxyphenamine may decrease the sedative activities of Doxylamine.	Experimental
Methsuximide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.	Approved
Methylecgonine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylecgonine.	Experimental
Methylene blue	Methylene blue may increase the anticholinergic activities of Doxylamine.	Approved, Investigational
Methylphenobarbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Methylphenobarbital.	Approved
Metyrosine	Doxylamine may increase the sedative activities of Metyrosine.	Approved
Midazolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Midazolam.	Approved, Illicit
Midomafetamine	Midomafetamine may decrease the sedative activities of Doxylamine.	Experimental, Illicit, Investigational
Milnacipran	The risk or severity of adverse effects can be increased when Doxylamine is combined with Milnacipran.	Approved, Investigational
Minaprine	Minaprine may increase the anticholinergic activities of Doxylamine.	Approved
Minocycline	Minocycline may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved, Investigational
Mirtazapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.	Approved
MMDA	MMDA may decrease the sedative activities of Doxylamine.	Experimental, Illicit
Moclobemide	Moclobemide may increase the anticholinergic activities of Doxylamine.	Approved, Investigational
Molindone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Molindone.	Approved
Morphine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Morphine.	Approved, Investigational
Nabilone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nabilone.	Approved, Investigational
Nalbuphine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nalbuphine.	Approved
Nefazodone	The risk or severity of adverse effects can be increased when Doxylamine is combined with Nefazodone.	Approved, Withdrawn
Nialamide	Nialamide may increase the anticholinergic activities of Doxylamine.	Withdrawn
Nitrazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrazepam.	Approved
Nitrous oxide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nitrous oxide.	Approved, Vet Approved
Norflurane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Norflurane.	Approved, Investigational
Normethadone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Normethadone.	Approved, Illicit
Nortriptyline	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Nortriptyline.	Approved
Octamoxin	Octamoxin may increase the anticholinergic activities of Doxylamine.	Withdrawn
Olanzapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olanzapine.	Approved, Investigational
Olopatadine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Olopatadine.	Approved
Ondansetron	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ondansetron.	Approved
Opium	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Opium.	Approved, Illicit
Orphenadrine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.	Approved
Osanetant	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Osanetant.	Investigational
Oxazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxazepam.	Approved
Oxetacaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxetacaine.	Approved, Investigational
Oxprenolol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxprenolol.	Approved
Oxybuprocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxybuprocaine.	Approved, Investigational
Oxycodone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxycodone.	Approved, Illicit, Investigational
Oxymorphone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Oxymorphone.	Approved, Investigational, Vet Approved
Paliperidone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paliperidone.	Approved
Paraldehyde	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.	Approved, Investigational
Pargyline	Pargyline may increase the anticholinergic activities of Doxylamine.	Approved
Paroxetine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Paroxetine.	Approved, Investigational
Penfluridol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Penfluridol.	Experimental
Pentazocine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentazocine.	Approved, Vet Approved
Pentobarbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pentobarbital.	Approved, Investigational, Vet Approved
Perampanel	Perampanel may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved
Perazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perazine.	Approved, Investigational
Perospirone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perospirone.	Approved
Perphenazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Perphenazine.	Approved
Pethidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pethidine.	Approved
Phenazocine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenazocine.	Experimental
Phenelzine	Phenelzine may increase the anticholinergic activities of Doxylamine.	Approved
Phenibut	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenibut.	Experimental
Pheniprazine	Pheniprazine may increase the anticholinergic activities of Doxylamine.	Withdrawn
Phenobarbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenobarbital.	Approved, Investigational
Phenoperidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenoperidine.	Experimental
Phenoxyethanol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenoxyethanol.	Approved
Phenoxypropazine	Phenoxypropazine may increase the anticholinergic activities of Doxylamine.	Withdrawn
Phentermine	Phentermine may decrease the sedative activities of Doxylamine.	Approved, Illicit
Phenytoin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Phenytoin.	Approved, Vet Approved
Pimozide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pimozide.	Approved
Pipamperone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipamperone.	Approved, Investigational
Pipotiazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pipotiazine.	Approved, Investigational
Piritramide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Piritramide.	Approved, Investigational
Pirlindole	Pirlindole may increase the anticholinergic activities of Doxylamine.	Approved
Pivhydrazine	Pivhydrazine may increase the anticholinergic activities of Doxylamine.	Withdrawn
Pizotifen	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pizotifen.	Approved
Pomalidomide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pomalidomide.	Approved
Pramipexole	Doxylamine may increase the sedative activities of Pramipexole.	Approved, Investigational
Pramocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pramocaine.	Approved
Prazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prazepam.	Approved, Illicit
Pregabalin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pregabalin.	Approved, Illicit, Investigational
Prilocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prilocaine.	Approved
Primidone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Primidone.	Approved, Vet Approved
Procaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Procaine.	Approved, Investigational, Vet Approved
Procarbazine	Procarbazine may increase the anticholinergic activities of Doxylamine.	Approved, Investigational
Prochlorperazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Prochlorperazine.	Approved, Vet Approved
Promazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promazine.	Approved, Vet Approved
Promethazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Promethazine.	Approved, Investigational
Propanidid	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propanidid.	Experimental
Proparacaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Proparacaine.	Approved, Vet Approved
Propofol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propofol.	Approved, Investigational, Vet Approved
Propoxycaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Propoxycaine.	Approved
Protriptyline	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Protriptyline.	Approved
Proxibarbal	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Proxibarbal.	Experimental
PSD502	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of PSD502.	Investigational
Pseudoephedrine	Pseudoephedrine may decrease the sedative activities of Doxylamine.	Approved
Quazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quazepam.	Approved, Illicit
Quetiapine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quetiapine.	Approved
Quinisocaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Quinisocaine.	Experimental
Raclopride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Raclopride.	Investigational
Ramelteon	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ramelteon.	Approved, Investigational
Rasagiline	Rasagiline may increase the anticholinergic activities of Doxylamine.	Approved
Remifentanil	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remifentanil.	Approved
Remoxipride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Remoxipride.	Approved, Withdrawn
Reserpine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Reserpine.	Approved, Investigational
Risperidone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Risperidone.	Approved, Investigational
Ritanserin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ritanserin.	Investigational
Ritobegron	Ritobegron may decrease the sedative activities of Doxylamine.	Investigational
Romifidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Romifidine.	Vet Approved
Ropinirole	Doxylamine may increase the sedative activities of Ropinirole.	Approved, Investigational
Ropivacaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ropivacaine.	Approved
Rotigotine	Doxylamine may increase the sedative activities of Rotigotine.	Approved
Rufinamide	The risk or severity of adverse effects can be increased when Rufinamide is combined with Doxylamine.	Approved
Safrazine	Safrazine may increase the anticholinergic activities of Doxylamine.	Withdrawn
Scopolamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.	Approved, Investigational
Secobarbital	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Secobarbital.	Approved, Vet Approved
Selegiline	Selegiline may increase the anticholinergic activities of Doxylamine.	Approved, Investigational, Vet Approved
Sepranolone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sepranolone.	Investigational
Sertindole	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sertindole.	Approved, Investigational, Withdrawn
Sertraline	The risk or severity of adverse effects can be increased when Doxylamine is combined with Sertraline.	Approved
Sevoflurane	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.	Approved, Vet Approved
Sodium oxybate	Sodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved
Stiripentol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Stiripentol.	Approved
Sufentanil	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sufentanil.	Approved, Investigational
Sulpiride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sulpiride.	Approved, Investigational
Sultopride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Sultopride.	Experimental
Suvorexant	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.	Approved, Investigational
Tandospirone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tandospirone.	Investigational
Tapentadol	Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Doxylamine.	Approved
Tasimelteon	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tasimelteon.	Approved, Investigational
Temazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Temazepam.	Approved, Investigational
Tetrabenazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrabenazine.	Approved, Investigational
Tetracaine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetracaine.	Approved, Vet Approved
Tetrahydropalmatine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrahydropalmatine.	Investigational
Tetrodotoxin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tetrodotoxin.	Investigational
Thalidomide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.	Approved, Investigational, Withdrawn
Thiamylal	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiamylal.	Approved, Vet Approved
Thiopental	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiopental.	Approved, Vet Approved
Thioridazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thioridazine.	Approved, Withdrawn
Thiothixene	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Thiothixene.	Approved
Tiagabine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiagabine.	Approved, Investigational
Tiapride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiapride.	Approved, Investigational
Tiletamine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tiletamine.	Vet Approved
Tilidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tilidine.	Experimental
Tizanidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tizanidine.	Approved, Investigational
Tolcapone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tolcapone.	Approved, Withdrawn
Toloxatone	Toloxatone may increase the anticholinergic activities of Doxylamine.	Approved
Topiramate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Topiramate.	Approved
Tramadol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tramadol.	Approved, Investigational
Tranylcypromine	Tranylcypromine may increase the anticholinergic activities of Doxylamine.	Approved, Investigational
Trazodone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trazodone.	Approved, Investigational
Triazolam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triazolam.	Approved, Investigational
Tricaine methanesulfonate	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Tricaine methanesulfonate.	Vet Approved
Trichloroethylene	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trichloroethylene.	Approved
Trifluoperazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluoperazine.	Approved, Investigational
Trifluperidol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trifluperidol.	Experimental
Triflupromazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.	Approved, Vet Approved
Trimipramine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Trimipramine.	Approved
Triprolidine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Triprolidine.	Approved
Valproic Acid	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Valproic Acid.	Approved, Investigational
Venlafaxine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Venlafaxine.	Approved
Veralipride	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Veralipride.	Experimental
Vigabatrin	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vigabatrin.	Approved
Vinyl ether	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vinyl ether.	Experimental
Vortioxetine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Vortioxetine.	Approved, Investigational
Xenon	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Xenon.	Experimental
Xylazine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Xylazine.	Vet Approved
Zaleplon	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zaleplon.	Approved, Illicit, Investigational
Ziconotide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziconotide.	Approved
Zimelidine	The risk or severity of adverse effects can be increased when Doxylamine is combined with Zimelidine.	Withdrawn
Ziprasidone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Ziprasidone.	Approved
Zolazepam	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolazepam.	Vet Approved
Zolpidem	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.	Approved
Zonisamide	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zonisamide.	Approved, Investigational
Zopiclone	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zopiclone.	Approved
Zotepine	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zotepine.	Approved, Investigational, Withdrawn
Zuclopenthixol	Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Zuclopenthixol.	Approved, Investigational

Food Interactions

Not Available

References

General References

Not Available

External Links

Human Metabolome Database: HMDB0001936
KEGG Drug: D02327
PubChem Compound: 3162
PubChem Substance: 46506354
ChemSpider: 3050
ChEBI: 51380
ChEMBL: CHEMBL1004
Therapeutic Targets Database: DAP000859
PharmGKB: PA449419
Drugs.com: Drugs.com Drug Page
Wikipedia: Doxylamine

ATC Codes

R06AA59 — Doxylamine, combinations

R06AA09 — Doxylamine

AHFS Codes

04:04.04 — Ethanolamine Derivatives

MSDS

Download (74 KB)

Clinical Trials

Clinical Trials

Phase	Status	Purpose	Conditions	Count
1	Completed	Not Available	Allergic Rhinitis (AR) / Upper Respiratory Infections	1
3	Completed	Prevention	Hyperemesis Gravidarum / Pregnancy	1
3	Completed	Treatment	Nausea and Vomiting of Pregnancy	1
4	Recruiting	Treatment	Morning Sickness	1

Pharmacoeconomics

Manufacturers

Not Available

Packagers

Amend
Centurion Labs
Chattem Chemicals Inc.
Deltex Pharmaceuticals Inc.
Duchesnay Inc.
Perrigo Co.

Dosage forms

Form	Route	Strength
Tablet, effervescent	Oral
Tablet, extended release	Oral
Capsule; kit	Oral
Capsule	Oral
Kit	Oral
Tablet, delayed release	Oral
Liquid	Oral
Capsule, liquid filled	Oral
Syrup	Oral
Capsule, gelatin coated	Oral
Tablet, coated	Oral
Tablet	Oral
Syrup	Oral	9.75 mg/5mL
Tablet, film coated	Oral
Kit; tablet	Oral
Powder, for solution	Oral
Solution	Oral
Tablet	Oral	25 mg
Kit
Tablet	Oral	25 mg/1

Prices

Unit description	Cost	Unit
Doxylamine succinate powder	1.5USD	g
Unisom sleep aid tablet	0.34USD	tablet
Sleep aid 25 mg tablet	0.15USD	tablet

DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.

Patents

Patent Number	Pediatric Extension	Approved	Expires (estimated)
US6340695	No	2001-06-21	2021-06-21
US7560122	No	1999-01-25	2019-01-25
US9526703	No	2013-02-18	2033-02-18
US9375404	No	2013-02-18	2033-02-18
US9089489	No	2013-02-18	2033-02-18

Properties

State

Liquid

Experimental Properties

Property	Value	Source
melting point (°C)	< 25 °C	PhysProp
boiling point (°C)	139 °C at 5.00E-01 mm Hg	PhysProp
water solubility	1 g/ml (succinate salt)	Not Available
logP	2.5	Not Available

Predicted Properties

Property	Value	Source
Water Solubility	0.541 mg/mL	ALOGPS
logP	2.9	ALOGPS
logP	2.96	ChemAxon
logS	-2.7	ALOGPS
pKa (Strongest Basic)	8.87	ChemAxon
Physiological Charge	1	ChemAxon
Hydrogen Acceptor Count	3	ChemAxon
Hydrogen Donor Count	0	ChemAxon
Polar Surface Area	25.36 Å²	ChemAxon
Rotatable Bond Count	6	ChemAxon
Refractivity	82.24 m³·mol^-1	ChemAxon
Polarizability	31.09 Å³	ChemAxon
Number of Rings	2	ChemAxon
Bioavailability	1	ChemAxon
Rule of Five	Yes	ChemAxon
Ghose Filter	Yes	ChemAxon
Veber's Rule	Yes	ChemAxon
MDDR-like Rule	No	ChemAxon

Predicted ADMET features

Property	Value	Probability
Human Intestinal Absorption	+	0.9505
Blood Brain Barrier	+	0.9491
Caco-2 permeable	+	0.746
P-glycoprotein substrate	Substrate	0.7449
P-glycoprotein inhibitor I	Non-inhibitor	0.5123
P-glycoprotein inhibitor II	Non-inhibitor	0.8383
Renal organic cation transporter	Inhibitor	0.7507
CYP450 2C9 substrate	Non-substrate	0.8153
CYP450 2D6 substrate	Non-substrate	0.5432
CYP450 3A4 substrate	Substrate	0.6801
CYP450 1A2 substrate	Non-inhibitor	0.9092
CYP450 2C9 inhibitor	Non-inhibitor	0.8957
CYP450 2D6 inhibitor	Inhibitor	0.8361
CYP450 2C19 inhibitor	Non-inhibitor	0.8764
CYP450 3A4 inhibitor	Non-inhibitor	0.6894
CYP450 inhibitory promiscuity	Low CYP Inhibitory Promiscuity	0.736
Ames test	Non AMES toxic	0.9133
Carcinogenicity	Non-carcinogens	0.9183
Biodegradation	Not ready biodegradable	1.0
Rat acute toxicity	2.9218 LD50, mol/kg	Not applicable
hERG inhibition (predictor I)	Weak inhibitor	0.8765
hERG inhibition (predictor II)	Inhibitor	0.5398

ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)

Not Available

Spectra

Spectrum	Spectrum Type	Splash Key
Predicted GC-MS Spectrum - GC-MS	Predicted GC-MS	Not Available
Mass Spectrum (Electron Ionization)	MS	splash10-0ab9-9200000000-5a71de62862f9881c2a1
MS/MS Spectrum - Quattro_QQQ 10V, Positive	LC-MS/MS	splash10-0040-0956300000-af11cf85a674e7db3735
MS/MS Spectrum - Quattro_QQQ 25V, Positive	LC-MS/MS	splash10-001i-0910000000-b3cb895f045d519f2bf3
MS/MS Spectrum - Quattro_QQQ 40V, Positive	LC-MS/MS	splash10-00kb-5597500000-8495062a84b32e776f33
Predicted MS/MS Spectrum - 10V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)	Predicted LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-qTof , Positive	LC-MS/MS	Not Available
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-001i-1920000000-07b98b36c7ef5d9ad048
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-001i-0900000000-1ae1143763892a7aac22
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-001i-0900000000-460d58a5bb6a5eb5f55b
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-0159-0900000000-34dc5c06413efae437da
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-014i-0900000000-8a5f15b863b7129c1288
LC-MS/MS Spectrum - LC-ESI-QFT , positive	LC-MS/MS	splash10-014i-0900000000-072ffba5139b7324d27a
MS/MS Spectrum - , positive	LC-MS/MS	splash10-00lr-0900000000-fdf3fc57eff19bfe8fd8
1H NMR Spectrum	1D NMR	Not Applicable
[1H,13C] 2D NMR Spectrum	2D NMR	Not Applicable

Taxonomy

Description: This compound belongs to the class of organic compounds known as benzylethers. These are aromatic ethers with the general formula ROCR' (R = alkyl, aryl; R'=benzene).
Kingdom: Organic compounds
Super Class: Benzenoids
Class: Benzene and substituted derivatives
Sub Class: Benzylethers
Direct Parent: Benzylethers
Alternative Parents: Pyridines and derivatives / Heteroaromatic compounds / Trialkylamines / Dialkyl ethers / Azacyclic compounds / Organopnictogen compounds / Hydrocarbon derivatives
Substituents: Benzylether / Pyridine / Heteroaromatic compound / Tertiary amine / Tertiary aliphatic amine / Azacycle / Organoheterocyclic compound / Ether / Dialkyl ether / Amine
Molecular Framework: Aromatic heteromonocyclic compounds
External Descriptors: tertiary amine, pyridines (CHEBI:51380)

Targets

Details1. Histamine H1 receptor

Kind: Protein
Organism: Human
Pharmacological action: Yes
Actions: Antagonist

General Function: Histamine receptor activity
Specific Function: In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamin...
Gene Name: HRH1
Uniprot ID: P35367
Uniprot Name: Histamine H1 receptor
Molecular Weight: 55783.61 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Details2. Muscarinic acetylcholine receptor M1

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Antagonist

General Function: Phosphatidylinositol phospholipase c activity
Specific Function: The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the...
Gene Name: CHRM1
Uniprot ID: P11229
Uniprot Name: Muscarinic acetylcholine receptor M1
Molecular Weight: 51420.375 Da

References

Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]

Details3. Nuclear receptor subfamily 1 group I member 3

Kind: Protein
Organism: Human
Pharmacological action: Unknown

General Function: Zinc ion binding
Specific Function: Binds and transactivates the retinoic acid response elements that control expression of the retinoic acid receptor beta 2 and alcohol dehydrogenase 3 genes. Transactivates both the phenobarbital re...
Gene Name: NR1I3
Uniprot ID: Q14994
Uniprot Name: Nuclear receptor subfamily 1 group I member 3
Molecular Weight: 39942.145 Da

References

Dring AM, Anderson LE, Qamar S, Stoner MA: Rational quantitative structure-activity relationship (RQSAR) screen for PXR and CAR isoform-specific nuclear receptor ligands. Chem Biol Interact. 2010 Dec 5;188(3):512-25. doi: 10.1016/j.cbi.2010.09.018. Epub 2010 Oct 20. [PubMed:20869355]

Enzymes

Details1. CYP2B protein

Kind: Protein
Organism: Human
Pharmacological action: Unknown
Actions: Inducer

General Function: Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function: Not Available
Gene Name: CYP2B
Uniprot ID: Q14097
Uniprot Name: CYP2B protein
Molecular Weight: 43147.81 Da

References

Bookstaff RC, Murphy VA, Skare JA, Minnema D, Sanzgiri U, Parkinson A: Effects of doxylamine succinate on thyroid hormone balance and enzyme induction in mice. Toxicol Appl Pharmacol. 1996 Dec;141(2):584-94. [PubMed:8975784]

Drug created on June 13, 2005 07:24 / Updated on May 26, 2018 08:45

Doxylamine

Identification

Structure for DB00366 (Doxylamine)

Pharmacology

Interactions

References

Clinical Trials

Pharmacoeconomics

Properties

Spectra

Taxonomy

Targets

References

References

References

Enzymes

References